CIC
FDMT icon

Cornercap Investment Counsel’s 4D Molecular Therapeutics FDMT Stock Holding History

Cornercap Investment Counsel’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-21,543
Closed -$173K – 590
2022
Q3 		$173K Hold
21,543
– – 0.03% 505
2022
Q2 		$150K Buy
+21,543
New +$209K 0.03% 504

Other funds holding FDMT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Cornercap Investment Counsel's FDMT Position: Q4 2022 in Review

Cornercap Investment Counsel sold out of 4D Molecular Therapeutics (FDMT) in Q4 2022, closing a stake of 21,543 shares — an estimated $173K sold.

Cornercap Investment Counsel first reported a position in FDMT in Q2 2022 and held it in 2 quarters. The position peaked at $173K in Q3 2022. 96 funds tracked by Wall St. Rank hold FDMT as of Q4 2022.

  • Cornercap Investment Counsel reported no remaining 4D Molecular Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Cornercap Investment Counsel sold 21,543 4D Molecular Therapeutics shares in Q4 2022, an estimated $173K.
  • Cornercap Investment Counsel first reported a position in 4D Molecular Therapeutics in Q2 2022 and held it in 2 quarters.
  • Cornercap Investment Counsel's 4D Molecular Therapeutics position peaked at $173K in Q3 2022.
  • 96 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q4 2022.

Based on Cornercap Investment Counsel's 13F filing for Q4 2022, filed 13 Feb 2023.